For now, of course. I certainly hope for the best with respect to cervical, but I think the winding down of the trial has been priced into the valuation of the company. The S-3 prospectus doesn't give any guidance or insight into how those discussions are going...not that they would divulge anything material in the middle of a prospectus, eh?
It could really go either way at this point, as you indicate. We'll see!
News 
Market Data 
Discover 
